Zhi Tong Cai Jing·2025-12-23 00:11Core Viewpoint - Fosun Pharma is acquiring a 51% stake in Green Valley Pharmaceutical through a combination of stock transfer and capital subscription, with a total investment of 1.269 billion yuan, structured to manage clinical and investment risks effectively [1][2]. Group 1: Acquisition Details - The acquisition involves a phased payment structure, with an initial payment of 635 million yuan at the time of closing and the remaining 634 million yuan to be paid within three years based on the company's R&D progress [1]. - The founder of the target company will pledge 10% of the company's shares post-acquisition to provide collateral against potential risks [1]. Group 2: Clinical Development - Fosun Pharma is committed to funding the clinical trials for the drug Ganluo Sodium Capsule, which will also be integrated into its innovative drug pipeline [1]. - The clinical trial for Alzheimer's disease has been revised to extend the double-blind medication period from 36 weeks to 48 weeks and increase the sample size from 1,312 to 1,950 participants, in line with the latest regulatory guidelines [2]. Group 3: Strategic Focus - Fosun Pharma is enhancing its product portfolio in the field of neurodegenerative diseases, aiming to address unmet clinical needs and strengthen its market position through a collaborative innovation model that includes both drugs and medical devices [3].